Floatz logo

70 assets in Prostate Neoplasm

Therapeutic assets addressing Prostate Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Docetaxel
Prostate Neoplasm
Merck Sharp & Dohme LLCP4BBB (73)
Degarelix
Prostate Neoplasm
Novartis PharmaceuticalsP4BBB (72)
Prednisone
Prostate Neoplasm
Merck Sharp & Dohme LLCP3BBB (72)
Abiraterone
Prostate Neoplasm
Qilu Pharmaceutical Co., Ltd.P3BB (71)
Leuporelin
Prostate Neoplasm
Dana-Farber Cancer InstituteP4BB (71)
Gozetotide
Prostate Neoplasm
Telix Pharmaceuticals (Innovations) Pty LimitedP3BB (68)
Prednisolone
Prostate Neoplasm
Eli Lilly and CompanyP3BB (68)
Apalutamide
Prostate Neoplasm
BayerP4BB (67)
Bicalutamide
Prostate Neoplasm
Wonju Severance Christian HospitalP4BB (66)
Goserelin
Prostate Neoplasm
Novartis PharmaceuticalsP4BB (66)
Olaparib
Prostate Neoplasm
Nuvation Bio Inc.P3BB (66)
Ctt-1057
Prostate Neoplasm
Novartis PharmaceuticalsP3BB (65)
Vipivotide Tetraxetan
Prostate Neoplasm
Novartis PharmaceuticalsP3BB (64)
Enzalutamide
Prostate Neoplasm
Qilu Pharmaceutical Co., Ltd.P3B (63)
Darolutamide
Prostate Neoplasm
BayerP3B (62)
Dexasone
Prostate Neoplasm
Merck Sharp & Dohme LLCP3B (62)
Piflufolastat
Prostate Neoplasm
Novartis PharmaceuticalsP2/3B (62)
Fludeoxyglucose
Prostate Neoplasm
National Cancer Institute (NCI)P2B (60)
Pembrolizumab
Prostate Neoplasm
GV20 TherapeuticsP3B (60)
Diphenhydramine
Prostate Neoplasm
Merck Sharp & Dohme LLCP3B (59)
Fludrocortisone
Prostate Neoplasm
Merck Sharp & Dohme LLCP3B (59)
Opevesostat
Prostate Neoplasm
Merck Sharp & Dohme LLCP3B (59)
Sar-Bispsma, Cu-64
Prostate Neoplasm
Clarity Pharmaceuticals LtdP3B (59)
Abemaciclib
Prostate Neoplasm
Eli Lilly and CompanyP3B (58)
AVOLVE
Prostate Neoplasm
CHU de Quebec-Universite LavalP2B (57)
Hydrocortisone
Prostate Neoplasm
Merck Sharp & Dohme LLCP3B (57)
Pertuzumab
Prostate Neoplasm
Cancer Research UKP2/3B (57)
Trastuzumab
Prostate Neoplasm
Cancer Research UKP2/3B (57)
Niraparib
Prostate Neoplasm
Janssen Research & Development, LLCP2B (56)
Ipilimumab
Prostate Neoplasm
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupP2CCC (55)
Dentalfluoro
Prostate Neoplasm
National Cancer Institute (NCI)P2CCC (54)
Ifinatamab Deruxtecan
Prostate Neoplasm
Merck Sharp & Dohme LLCP3CCC (54)
NSAA
Prostate Neoplasm
University of SydneyP3CCC (54)
Relugolix
Prostate Neoplasm
Dana-Farber Cancer InstituteP2CCC (54)
Testosterone Undecylate
Prostate Neoplasm
Canisius-Wilhelmina HospitalP3CCC (54)
Fezolinetant
Prostate Neoplasm
Shehzad Basaria, M.D.P2CCC (53)
Fluorine (18F) Psma 1007
Prostate Neoplasm
Primo Biotechnology Co., LtdP2CCC (53)
Flotufolastat F 18
Prostate Neoplasm
Icahn School of Medicine at Mount SinaiP2CCC (51)
Nivolumab
Prostate Neoplasm
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupP2CCC (51)
pds01adc
Prostate Neoplasm
National Cancer Institute (NCI)P1/2CCC (48)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Prostate Neoplasm
National Cancer Institute (NCI)P1/2CC (46)
177Lu-rhPSMA-10.1
Prostate Neoplasm
Blue Earth Therapeutics LtdP1/2CC (43)
Adv/Hsv-Tk
Prostate Neoplasm
The Methodist Hospital Research InstituteP1/2CC (43)
Autologous Neoantigen-Pulsed Dendritic Cell Vaccine
Prostate Neoplasm
Changhai HospitalP1CC (43)
ly4257496
Prostate Neoplasm
Eli Lilly and CompanyP1CC (43)
Nuv-868
Prostate Neoplasm
Nuvation Bio Inc.P1CC (43)
qlh12016
Prostate Neoplasm
Qilu Pharmaceutical Co., Ltd.P1/2CC (43)
Talogreptide Mesaroxetan
Prostate Neoplasm
Clarity Pharmaceuticals LtdP1/2CC (43)
Valaciclovir
Prostate Neoplasm
The Methodist Hospital Research InstituteP1/2CC (43)
CARTIA
Prostate Neoplasm
Merck Sharp & Dohme LLCP1CC (42)
Showing 1 to 50 of 70 assets
PreviousPage 1 of 2Next